
Natera (NTRA) Stock Forecast & Price Target
Natera (NTRA) Analyst Ratings
Bulls say
Natera Inc. is experiencing significant revenue growth driven by its Signatera molecular residual disease test, which reported a 54% year-over-year increase in volumes. The company anticipates expanding its reimbursement coverage for additional cancer types, potentially leading to increased average selling prices (ASP), improved gross margins, and enhanced operating cash flow. Furthermore, Natera's impressive performance in the most recent quarter includes an approximately $80 million revenue beat, alongside a raised revenue guidance for 2025, reflecting continued positive momentum.
Bears say
Natera Inc. faces a negative outlook due to anticipated margin erosion stemming from reductions in in-network pricing as it expands its total addressable market (TAM) to include more average-risk patients. Regulatory setbacks, reimbursement issues, or delays in product launches could further amplify financial vulnerabilities, potentially leading to significant stock depreciation. Additionally, challenges related to compelling data and adoption in emerging markets may hinder the company's growth prospects, raising concerns about its ability to achieve projected financial targets.
This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.
Natera (NTRA) Analyst Forecast & Price Prediction
Start investing in Natera (NTRA)
Order type
Buy in
Order amount
Est. shares
0 shares